| DB ID | MyCo_3964 |
| Title | Markers of potential malignancy in chronic hyperplastic candidiasis |
| Year | 2012 |
| PMID | 22489001 |
| Fungal Diseases involved | Chronic hyperplastic candidiasis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | spp. |
| Organism | Candida spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Biopsy |
| Sample source | Extracted Tissue |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | PCNA |
| Biomarker Full Name | Proliferating cell nuclear antigen |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Canada |
| Cohort | Forty-two consecutive CHC lesions were identified from the archives of the Department of Pathology at the Uni- versity of Western Ontario, Ontario, Canada. |
| Cohort No. | 42 |
| Age Group | 57 |
| P Value | p=0.0007 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Chronic hyperplastic candidiasis (CHC) is commonly diagnosed in the oral cavity, and has previously been associated with cancerous change.1–4 Candida albicans strains have been suggested to play a causal role in the development of oral cancer by means of endogenou nitrosamine production. |
| Technique | Immunological assay |
| Analysis Method | Immunohistochemistry |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Immunohistochemistry |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
